Enter your search term above.

News

Elizabeth de Jong passed away on July 3, 2023 from complications caused by Stage IV lung cancer.


July 2017 | As told by Elizabeth de Jong

On September 16, 2016, my life took a sharp right turn. I had been having some hip pain over the summer and it had stretched down into my thigh by August. A visit to the orthopedist resulted in one of those awesome “women at your age” conversations and a shot for bursitis. The x-ray had stopped just shy of the tumors that were in my femur. A few days before I was due for a follow up appointment with the orthopedist, my femur broke as I was going down the stairs in my house. At the hospital in viewing my x-rays, the same orthopedist, feeling bad that he hadn’t caught them the first time he saw me in August, saw the tumors and ordered an MRI and more x-rays. He didn’t like what he saw and referred us to a comprehensive cancer center of our choosing. After nearly a week of more x-rays and CT scans and MRIs, and a bronchoscopy, I was told I had non-small cell lung cancer, stage IV. In addition to the femur, they had found tumors in the lower lobe of my right lung, lymph nodes near it and a lesion in my brain. Shocked doesn’t even begin to describe how I felt. Shocked not only at the diagnosis but also in disbelief because, other than the hip and leg pain, I’d had no symptoms – no shortness of breath, no coughing, no pain, no headaches, no vision issues, nothing.

When I heard those words “lung cancer” I thought the typical thoughts – I’m too young. I don’t want to die yet. My world stopped rotating and for a moment, the only things I could feel were the pain and fear in my heart and my husband’s hand in mine. Then the world came back into focus and my amazing medical team from Hillman Cancer Center at the University of Pittsburgh Medical Center rallied around me. My biopsies and blood were sent out for genomic testing. I was scheduled for cyber knife on my brain and radiation on my now-repaired and titanium reinforced leg. As we wrapped up the radiation treatments, my genomic testing came back and I was told I’d hit the “jackpot” of NCSLC – ALK – non small cell lung cancer with the anaplastic lymphoma kinase mutation. Fewer than 5% of all NCSLC diagnosis share this trait but research has created a great window of treatment opportunities.

My husband is my co-fighter, my warrior, my researcher, my advocate, my laughter, my shoulder to cry on, and my true partner. I refer to “our” oncology appointments because he never misses one. He’s been with me for every treatment, as close as the radiation techs would allow – far down the hallway behind the lead walls but still with me every step of the way. But that is just the details of what he does, what doesn’t come through is how much my love has grown for him since we started this journey. He helps me in more ways than I can even try to articulate. Together, we stay as positive as possible: enjoy good food, friends, travel and much much more. He knows when I’m struggling and can appropriately be my cheerleader or, if needed, remind me to get over myself.

Chemotherapy

My treatment is an “oral chemo” or, more appropriately, a tyrosine-kinase inhibitor. I started, for just a few weeks with Xalkori®, crizotinib, but quickly transitioned to Alecensa®, alectinib. It better crosses the blood/brain barrier and since I’d already had one lesion, our oncology team decided to make the switch. My oncologist strikes a good balance between realist and optimist. We talk about not only my current treatments but what will come next or down the line from that. He’s explained about TKI immunity or failure. We’ve talked about options for other TKIs, other therapies, potential trials, if appropriate, and additional biopsies and testing when failure happens (a reality – whether this year or next year or the next). I’m hoping for a good long run on alectinib but also keep in the back of my mind that eventually its effectiveness will come to an end.

I’ve been fortunate to have very few side effects from either the radiation or the daily regimen of oral chemo. One of the challenges, I think, that cancer patients face as medical science advances is that we don’t look like “typical” movie or tv cancer patients. I haven’t, and won’t, lose my hair with this treatment; I am able to work full time, travel and work out. Because I have not received “traditional” chemotherapy, I don’t have a port and I don’t have many of the side effects most people think of when they think of cancer. I do get tired more easily. I do have some muscle and joint aches and pains as a side effect of the alectinib. The alectinib is a photosensitive drug and I’ve learned that SPF 50 won’t cut it for me anymore. I don’t have any dietary restrictions and, other than my own sweet tooth that goes back to way before my cancer diagnosis, am able to eat a normal diet.

Another challenge I faced was getting off the walker, and then off a cane, after my femur repair. This took a lot of time and I had to be patient and remind myself that I couldn’t expect “normal” results because I was no longer normal. I was not only healing a broken femur but fighting the cancer in the bone, and the rest of my body, and dealing with the radiation to my femur as well. I had great days where I would do so much more than I thought I could the day before and then days where I struggled to even do the bare minimum to get through the day.

I’m fortunate that we have both access to and resources for complimentary therapies – regular yoga, acupuncture, therapeutic massage and physical therapy/training sessions along with a naturopath and nutritionist as needed. Other than that pesky cancer, I’m probably healthier than I have been at any other time in my adult life.

Celebrating life in 3-month increments

There are days when I could ALMOST forget I have cancer. I feel strong and healthy. But then it’s time to take another medication or supplement and I’m reminded. In addition to daily workouts, trying to eat a more healthy diet, and my medication regimen, I’ve added a few other activities. I journal nightly. I track symptoms and side effects in my journal, in addition to my emotions or daily activities. I also keep a daily prayer list of people I want to include in my thoughts and prayers that day – some people are, and have been, on that list daily since I started, others come and go based on what I see on social media, what is shared with me in conversation or just a feeling I might get about that person. That prayer list also includes prayers for me – –vary from day to day as well. I try to think positively, that I’m doing well and the treatments are working. But there are times that the reality sinks in. I worry about what progression may look like for me, since each person’s journey is different. I worry about having to tell my family and friends about that progression. I find myself trying to reinforce to people that I’m fine, while in my head I’m thinking “I’m fine, for now.” But I don’t want to bring people down.

I let myself have small pity sessions from time to time but then I try to move past it. I think about the trips I can still take (can you tell my husband and I love to travel?), the time with friends and family that I still have, the mundane day-to-day events I still have in front of me, and all the good things ahead of me. We celebrate life in 3-month increments between scans.

I received some great pieces of advice from various people when I started this journey. I met a gentleman a few months ago while I was waiting for my first follow-up MRI. He was just starting his cancer journey, getting scans to figure out what needed to be removed in the next day’s operation. His fear and sense of being overwhelmed were palpable. We talked and shared our stories, and he asked me for my advice (even though he wasn’t dealing with lung cancer). I passed along what was working for me in the moment. I recommended the journaling I do, trying to stay as positive as possible but to not ignore the realities of your cancer and treatments, finding the people that make you feel the best and keeping them in your life, eliminating things that don’t bring you joy or positivity, exercising when and how you can, informing yourself about your diagnosis from reliable sources (DO NOT rely on Dr. Google!), eating well, and watching for the angels in your life. He told me I was an angel for him but in reality, he was an angel for me that day. Seeing him, in raw emotion and having him share his fears with me, let me see myself and also let me see how strong we both were – facing cancer head on.

At the Free to Breathe Walk

My recent triumphs include walking a 5K for Free to Breathe (now merged with the Lung Cancer Research Foundation) and being the number one fundraiser for our walk (and number two in the nation at the time!). I walked that 5K without my cane. I walked that 5K with other survivors and thrivers. I walked that 5K with a widower who buried his wife after her too-short battle with lung cancer. I told my story then, and now, to share with the world, or at least, my corner of it, that lung cancer doesn’t just come for the smokers, the coal miners, or the asbestos workers. Lung cancer claims more lives than breast, prostate and colon cancer, combined. But the research dollars don’t reflect that and need to keep coming in. Funding for other cancers far out paces that for lung cancer yet all it takes for anyone to be at risk for lung cancer is a lung. I want to spread the word and I want research to keep moving forward and staying one step ahead of my cancer so I have more treatment options to keep extending my life for a long time to come.

March 2017

My mother died of lung cancer, and I was secretly worried I would, too.

In spring 2008, I had some puzzling health issues that brought me to number of specialists and finally a pulmonologist. I confessed during one of my appointments that I had smoked for several years, although I had quit 15 years earlier.

He did a spiral CT and told me in no uncertain terms that I did not have lung cancer. We continued the diagnostic journey, and he finally discovered a tracheal stenosis. Yet another specialist treated me with a procedure to dilate the trachea. What a relief it was to breathe more easily – in more ways than one. After many years of wondering, I finally knew that I did not have lung cancer.

A few months later, I started coughing up small amounts of blood. My doctor suspected sinus issues, but to be on the safe side, he went back in to look at my trachea. He found a tumor breaking through the lower lobe into the middle lobe of my right lung.

I had surgery to remove the lower and middle lobes of my lung and was diagnosed with Stage IIIa lung cancer. Following a fairly quick recovery period, I began four rounds of chemotherapy – two weeks on, one week off – with Cysplatin and Gemcytabin. That was hard. I was given a 38% chance of surviving five years. I agreed to participate in a phase 3 clinical trial for Erlotinib – Tarceva. Although my diagnosis was devastating, I knew I could survive.

After treatment, it took me some time to recover. I was working full time and began a vigorous exercise routine. It took about a year to feel healthy and strong again, but I finally felt great. I became quite a vocal lung cancer patient.

I wasn’t prepared for the judging nods that whispered, “Lung cancer? Oh, you smoked, well…” The fact is that my smoking did not cause my lung cancer. My cancer and my mother’s were both caused by radon, which is an issue in my home state of Oregon. I grew up in areas with especially high radon levels. I wanted to put a new face on lung cancer and didn’t hide my diagnosis. I still don’t. I educate others as often as I can about lung cancer and radon, particularly about the disparity in funding for lung cancer research.

Breathing issues return

Six years after treatment – in spring 2015 – I began experiencing new breathing issues. I wasn’t too worried, as all my scans since my first post-surgical exam had been clean. My doctor discovered another tracheal stenosis. I joked, “Be careful now, the last time you went in there, I came out with Stage III lung cancer.”

Little did I know, I had cancer cells in my lung near the original surgical site. Again, I was devastated. But the next day, I took a deep breath and figured out what to do next. The next several months were full of more tests, and even more differing opinions. They could remove the rest of the lung. High dose radiation and chemo had a 90% success rate.

Well, the cancer cells were located too close to my esophagus to risk high dose radiation, so the radiation oncologist was only comfortable with a low dose – which had a 30% success rate. After running multiple tests, my surgeon felt I could tolerate the complete loss of my lung. I chose the surgery, but the day before it was to take place, the surgeon called me with another option. He thought he could get rid of the cells with laser ablation in a simple office visit.

I had the ablation. Unfortunately, a biopsy one month later showed remaining cancer cells, and a new lymph node tested positive. I felt so lost. I didn’t know who to trust or what to do. I knew I needed to decide on my next step, but I didn’t feel capable of making that choice.

Finally, I called my original oncologist, who had moved out of state. I asked him if he would look at my scans and other test results and give me his opinion. A few days later, he called to say he agreed with my current medical oncologist – he felt I should undergo low dose radiation and chemotherapy.

I immediately relaxed and knew that was the right decision. I trusted him, and I was confident I could handle the treatment. After all, I’d done chemo before and radiation couldn’t make it that much different. For six weeks, I underwent daily radiation and chemo – this time it was Cysplatin and Etoposide. I grossly underestimated the side effects of radiation. I’d managed to care for myself during my first bout with lung cancer, but never would have been able to do so the second time without the help of my sister. She was invaluable. I finished treatment almost a year ago. Although I’m not quite 100% better, I’m close.

Hope for the future

I remain optimistic for my future and the future of lung cancer treatment. I’m participating in a phase 2 clinical trial for a lung cancer vaccine, and the data is promising. I’m an active supporter of Free to Breathe (now merged with the Lung Cancer Research Foundation) and its specific focus on lung cancer research. (The photo at the top was taken at the August 2016 run/walk in Portland. My team is Positively Breathtaking!) I hope to work within the state of Oregon to improve the general public’s knowledge of radon and its life-changing effects.

I appreciate the opportunity to share my story with you and would like to ask you to do two things. First, help me reduce the stigma and change the face of lung cancer.

Second, be your own advocate. Listen to your body. Find a healthcare provider that you trust instinctively. Both times I had lung cancer, my body tried to tell me something was wrong. If I had listened to those who recommended I stop at any point along my now eight-year journey, I believe the outcome would have been much more grave.

Springtime twice brought me a lung cancer diagnosis. This spring, I am beginning a new journey that brings me joy. I am frequently reminded of a quote by Christopher Reeve. “Once you choose hope, anything is possible.”

July 2016

As a school teacher, I’m on my feet much of the day and was having some odd symptoms. I was told by the nurse at the school to see a doctor, and when I had passed at out school I was taken to the hospital and later diagnosed with lung cancer. Originally doctors thought it was stage 4 adenocarcinoma, but it was later restaged to stage 1B lung cancer. I was only 29 at the time, and it was all I could think about. I was very anxious and overwhelmed by all of the unknowns associated with my diagnosis.

I ended up having surgery. The top left lobe was removed, and I had 4 rounds of chemotherapy. I was not eligible for a clinical trial, but would have considered one. I had two mutations, but there were no trials at the time. Today, my condition is stable, and I have been blessed with two wonderful children!

After surgery, I had lost my voice and had to adapt to my new lung capacity. This was a big challenge, because as a teacher I needed to be able to yell or read a book at any moment of the day without thinking twice.

Life after treatment was all consuming of my emotions and energy, but I had a strong support system throughout the whole process. My mother took me to all of my appointments, scans and chemotherapy. I leaned on those closest to me. My friends and family were a big help.

I found a few things to help make my journey with lung cancer easier. I avoided reading too much on the internet. There is so much out there, and it can be overwhelming. I also did not ask the doctor questions that I didn’t want to know the answer to. All of the medical terminology was just too overwhelming to me. I put my trust in my medical team.

There are a ton of resources available for people living with other cancers, such as breast and prostate, but very few for lung cancer. It can be hard to find a support group for lung cancer survivors, but I highly recommend getting “plugged in” with one. Just talking to someone who has been there can be helpful, and it can be therapeutic to share your own story.

In the 4 years since my diagnosis, I started Cassie’s Crew in the Dallas Free to Breathe Walk and become an involved advocate, committee member, team captain, donor and ambassador, raising over $110,000 for lung cancer research with my team. It has been a great way to give back and stay connected to the lung cancer community.

May 2017 | As told by Beth

I wasn’t home for Christmas in 2012: I was in the hospital with mysterious respiratory symptoms, and a stubborn “walking pneumonia” that hadn’t responded to antibiotics or steroids.

The new year brought further challenges. Just after New Year’s Day 2013, I received a phone call with the official news that I had been diagnosed with advanced non-small cell lung cancer. I’d had a biopsy while I was in the hospital, so I knew cancer was a possibility. It seemed so impossible, though. All I knew about lung cancer was its association with smoking, and I had never smoked.

I didn’t know anyone with lung cancer or anyone who’d experienced it in their family, or so I thought. I felt alone and didn’t know where to go for help. At first I got most of my information from my doctors and was fortunate to have access to specialists at some of the top cancer centers in the country. When a thoracic surgeon told me that my cancer was Stage IIIb or IV, that I was not a candidate for surgery and that my cancer was not curable, I was devastated.

I will always be grateful to Dr. Biren Saraiya, the medical oncologist who managed my treatment for the first six months. He was patient, compassionate, and knowledgeable. With his help I came to understand that even if my disease couldn’t be cured, with treatment I could have a good quality of life.

When standard chemotherapy didn’t seem to be helping me, Dr. Saraiya encouraged me to find out what clinical trials might be open to me. I knew something about clinical trials from briefly being an AIDS activist in the 1990s, so I understood that trials could be the best way to get access to the newest and most promising treatments. Also, even if a trial medicine didn’t help me, at least by taking part in the trial I could help future patients by contributing to knowledge about this disease.

I had another biopsy, and my cancer tissue was sent off to be tested for any mutation or substance that might provide a clue as to what trial might be best for me. That testing resulted in a wonderful surprise, although at the time I had no idea how wonderful: my cancer had the ROS1 genetic mutation. The data was already showing that one of the new targeted therapies, crizotinib (now better known by the brand name Xalkori), was very effective against ROS1 cancer. The research team enrolled me in the study and I started taking crizotinib right away. The results were amazing: within days I felt better, and within months my cancer was no longer visible on CT scans.

I had never heard of Free to Breathe (now merged with the Lung Cancer Research Foundation) until my friend Michelle signed me up for a lung cancer walk in my hometown, Philadelphia. Years before, I had run a marathon to raise money for the Leukemia and Lymphoma Society in honor of Michelle, a lymphoma survivor. Now the tables were turned, and she organized a team to walk and raise money in my honor. We walked with our mothers and our children, and that year our team was one of the most successful at raising funds.

It’s been important to me to connect with other lung cancer survivors. I’ve taken part in two more Free to Breathe walks, and attended an action summit. I’m part of a lung cancer group on social media (hashtag: #lcsm) and a Facebook group especially for people with the ROS1 mutation. It’s through the community of survivors that I now stay up to date on current treatment news.

I think that this moment in lung cancer history is a little bit like the moment in AIDS history in 1996, when the combined power of engaged patients and inspired activists pushed research over a tipping point and all of a sudden a deadly disease became, for many, a chronic but manageable condition. We may not be quite at that tipping point yet, but I can’t help believing it’s very close.

Photo credit: Donna Uettwiller. Donna was part of Beth’s first Free to Breathe team, and Donna’s daughter won the 5K in her age group.

NEW YORK, November 12, 2019 — Today the Lung Cancer Research Foundation® (LCRF) announced the awardees of its 2019 Scientific Grant Program during the Fourteenth Annual Lung Cancer Awareness Luncheon, held at The Pierre in New York City. Through this program, LCRF awarded $2.6 million in research grants to 12 investigators whose projects focus on basic, translational, clinical, health services and epidemiological research. In addition to its annual pilot grants, for the first time, LCRF awarded research grants through two additional funding mechanisms: one focused on overcoming disparities in lung cancer and one on improving the effectiveness of targeted therapies.

LCRF is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. To date, LCRF has funded 370 research grants totaling nearly $34 million, the highest amount provided by an organization dedicated to funding lung cancer research.

“As a lung cancer researcher and former LCRF grantee, I know first-hand the importance and impact LCRF’s funding has on the careers of junior scientists,” said Katerina Politi, PhD, Chair of LCRF’s Scientific Advisory Board and Clinical Biologist and Associate Professor at Yale’s School of Medicine. “Through the grant program, LCRF supports both cutting-edge lung cancer research and researchers. We are confident that these projects will lead to advancements that will ultimately have a direct impact on lung cancer patients.”

Through its annual pilot grant program, LCRF funds innovative research focused on the prevention, diagnosis, treatment and cure of lung cancer. This year, LCRF will be funding four projects through this mechanism. Among them are the prestigious James B. Dougherty Award for Scientific Merit and the William C. Rippe Award for Distinguished Research in Lung Cancer. The James B. Dougherty Award for Scientific Merit is named in honor of Dr. James Dougherty, who served as the Chair of the LCRF Scientific Advisory Board for the past 13 years and is responsible for stewarding the growth of the grant program. The award is presented to the investigator whose proposal was selected for outstanding overall merit by the Foundation’s Scientific Advisory Board. This year’s recipient is Lingtao Jin, PhD, Assistant Professor at the University of Florida in the Department of Anatomy and Cell Biology. Dr. Jin’s research project is titled, “The role of protein kinase signaling in cisplatin-resistant ASCL1-high subtype small cell lung cancer.”

“It is my distinct honor to receive the James B. Dougherty Award for Scientific Merit,” said Dr. Jin. “This award provides critical support and funding to investigate the development of chemotherapy resistance in small cell lung cancer.”

LCRF’s William C. Rippe Award for Distinguished Research in Lung Cancer is presented to the investigator whose proposal not only demonstrated exceptional scientific merit but also exemplified an enduring commitment to making an impact in the field of lung cancer research. Benjamin Lok, MD, Clinician Scientist at the University of Toronto’s Princess Margaret Cancer Centre, was named the 2019 recipient of this award. His research project is titled, “Investigating a resistance mechanism mediated by a Skp, Cullin, F-box containing E3 ubiquitin ligase complex in small cell lung cancer.”

“I am incredibly honored to receive the William C. Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation,” said Dr. Lok. “This award is a testament to and recognition for the work my laboratory and clinical teams do every day towards the goal of improving outcomes for patients with lung cancer. We do this in partnership with our patients and colleagues – therefore this award is also for them.”

LCRF’s funding mechanism focused on overcoming disparities in lung cancer was founded with support from the Stavros Niarchos Foundation (SNF), in loving memory of Kathryn Louloudis. This year, LCRF will be funding four projects in this area, supported by additional corporate partners, focused on topics including gender, racial, and socioeconomic disparities in care and outcomes. These projects will address important questions across the care continuum and ultimately help to overcome the significant gaps in health equity among lung cancer patients.

Through a collaboration with Pfizer Inc., LCRF will be awarding four research grants focused on understanding ways to improve clinical practices for managing side effects in patients with non-small cell lung cancer (NSCLC) who are receiving targeted therapies. These research projects will leverage multidisciplinary approaches to help patients and their care teams manage side effects and receive the maximum possible benefit of these important therapies. This Lung Cancer Treatment Focused Research Grant Program is the first collaboration of its kind in lung cancer and is very important and timely to the many patients receiving targeted therapies.

In addition to the presentation of the 2019 Scientific Grant Program awards, LCRF’s Lung Cancer Awareness Luncheon featured two guest speakers. Giuseppe Giaccone, MD, PhD, Associate Director for Clinical Research at Cornell University delivered the keynote address. LCRF Board Member and lung cancer survivor Reina Honts shared her experience and talked about the importance of research funding and early detection.

The 2019 Pilot Grant Program award recipients include*:

Alice Berger, PhD
Fred Hutchinson Cancer Research Center
Novel strategies for therapeutic target discovery in lung cancer

Lingtao Jin, PhD
University of Florida
The role of protein kinase signaling in cisplatin-resistant ASCL1-high subtype SCLC

Benjamin Lok, MD
Princess Margaret Cancer Centre, University of Toronto
Investigating a resistance mechanism mediated by a Skp, Cullin, F-box containing E3 ubiquitin ligase complex in small cell lung cancer

Zhan Yao, PhD
Memorial Sloan Kettering Cancer Center
Studies on the oncogenic function and mediation of drug resistance by ARAF in lung cancer

The 2019 Disparities in Lung Cancer Research Grant Program award recipients include*:

Melinda Aldrich, PhD, MPH
Vanderbilt University Medical Center
Identifying determinants of racial disparities in lung cancer stage

Manali Patel, PhD, MPH
Stanford University
Reducing disparities in lung cancer through community partnerships

Betsy Risendal, PhD
University of Colorado Denver
Improving preventive care to address lung cancer disparities

Rajwanth Veluswamy, MD
Icahn School of Medicine at Mount Sinai
Assessing the mechanisms underlying the association between sex and immunotherapy response

The 2019 Lung Cancer Treatment Focused Research Grant Program award recipients include**:

Ryan Gentzler, MD
University of Virginia
Real-time monitoring and modeling of symptoms and adverse events in lung cancer patients receiving oral targeted therapies for tumors with oncogenic driver mutations

Nisha Mohindra, MD
Northwestern University Feinberg School of Medicine
Using the novel 4R patient care sequences to improve the duration and outcomes of therapy in NSCLC patients receiving targeted treatment

Katharine Rendle, PhD, MSW, MPH
University of Pennsylvania
Implementation strategies for monitoring adherence in real-time (iSMART)

Christian Rolfo, MD, PhD, MBA
University of Maryland, Baltimore
Proactive monitoring of treatment related adverse events through a mobile application in NSCLC patients treated with tyrosine kinase inhibitors: the “Empower Me” Digital Therapeutic Study

For more information about LCRF and the Scientific Grant Program, visit lcrf.org.

*These grants provide up to $150,000 in funding over a two-year period
** These grants provide up to $350,000 in funding over a two-year period

###

About the Lung Cancer Research Foundation®
The Lung Cancer Research Foundation (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. To date, LCRF has funded 370 research grants, totaling nearly $34 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research. For more information, visit lcrf.org.

NEW YORK (November 8, 2019) —In the United States, lung cancer claims more women’s lives each year than breast, ovarian, and cervical cancers combined. In many countries around the world, it has become the leading cause of cancer death in women. This November and December, the Lung Cancer Research Foundation® (LCRF) is shining a spotlight on women and lung cancer, with the goal of educating the public about these staggering statistics.

“Everyone has women in their life—a loved one, friend, co-worker—so this disease truly does impact everyone,” said Joan H. Schiller, MD, Chair of LCRF’s Scientific Steering Committee. “Our goal is to raise awareness to better understand lung cancer risks, particularly for women, and improve outcomes for those diagnosed.”

Worldwide, lung cancer is the leading cause of cancer mortality in women and over 500,000 women die of the disease each year. While lung cancer incidence remains lower in women than in men, the gap has been narrowing in recent years. With a higher proportion of lung cancer among nonsmokers occurring in women, these are troubling statistics. In an effort to raise awareness, LCRF has created a page on its website dedicated to women and lung cancer, http://lcrf.org/women. Visitors will learn the facts about lung cancer and will have the opportunity to read stories of women currently living with lung cancer.

LCRF is the leading nonprofit organization focused on funding innovative, high-reward lung cancer research with the potential to extend survival and improve quality of life for people with lung cancer. The organization’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. This campaign, focused on women and lung cancer, will help to highlight an important area that warrants additional study. “By talking about these grim statistics, we hope to raise awareness and highlight the importance of research and how lung cancer is affecting women,” said Schiller.

To learn more information and download a fact sheet on women and lung cancer, visit http://lcrf.org/women. This initiative is sponsored by Bristol-Meyers Squibb, Genentech and Takeda Oncology.

# # #

About the Lung Cancer Research Foundation

The Lung Cancer Research Foundation® (LCRF) is the leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve quality of life for people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer.

To date, LCRF has provided $33 million in research grants to investigators around the world. In addition to funding lung cancer research, the organization focuses on lung cancer awareness and educational programs. The Foundation also hosts community events nationwide through the Free to Breathe Events Program. For more information, visit http://lcrf.org.

A team of 10 runners represented the Lung Cancer Research Foundation at the TCS New York City Marathon on Sunday, November 3. The group, made up of first-time marathoners and veterans alike, all ran in support of lung cancer research and awareness, a cause that hits close to home.

“As a thoracic oncologist myself who has worked for the last close to 20 years with countless patients suffering from lung cancer and who also actively participated in both clinical and translational research, I plan to run in memory of patients we have lost, in support of patients I am currently following and in great hopes for future generations of patients who we will be able to help better expecting great research advances ahead – as long as we can find the funding to keep our talented and motivated young scientists in our field through the help of foundations such as LCRF,” said Team LCRF runner Dr. Balazs Halmos, shown at right.

Team LCRF crushed the marathon, and they also crushed their fundraising goal, raising over $70,000 for lung cancer research!

Many of LCRF’s investigators, including Scientific Advisory Board Chair Dr. Katerina Politi, presented at this year’s IASLC 20th World Conference on Lung Cancer in Barcelona. The discussions at this year’s conference highlighted the importance of lung cancer screening, biomarker testing, and advocating for more lung cancer research funding.

Dr. Katerina Politi provides an overview of how resistance to targeted therapies impacts lung cancer outcomes.

LCRF’s Senior Manager of Education and Outreach, Cristina Chin, represented the organization at the annual meeting of the Global Lung Cancer Coalition, which took place just days before. More research funding will make all the difference in lung cancer outcomes!

WCLC on Twitter



Read more on Twitter

Kortni with Lesley

Kortni and Tiffany are sisters who lost a close friend, Lesley Demaio Duffy, at way too young an age. Lesley was only 38 – and pregnant with her second child – when she was diagnosed with lung cancer. Not only was Lesley in the prime of her life, she was healthy, active, and had never smoked.

When Lesley died on July 15, 2018, she left behind her husband, Chris, and two small children. Lachlan was just 3 years old when his mom was diagnosed, and Camden was born shortly after.

Tiffany with Lesley
Tiffany with Lesley

“She was robbed of her future by this silent killer,” said Kourtni. “But she was lucky in some ways. At the time of her diagnosis, a new drug hit the market – it treated her specific type of lung cancer and gave her another two-and-a-half years with us.”

Tiffany and Kortni decided to form a team for the Chicago Lung Run so they could support research that would give others more time with their loved ones. Currently, Team DeMuffy is the event’s top fundraising team, raising nearly $20K.

At the Chicago Lung Run kickoff, the sisters shared the top two reasons for their success. “Tell people why raising money and funding lung cancer research is important to you,” Tiffany said. “Not only does this create awareness, but it also helps break the stigma associated with lung cancer.”

Their other tip? “Ask everyone you know,” said Kortni. “If you don’t ask, they can’t give!”

On event day, Tiffany was interviewed on Chicago’s Fox 32. See the clip below.

The FDA approved a targeted therapy entrectinib (Rozlytrek) for either NTRK+ solid tumors or ROS1+ patients with metastatic non-small cell lung cancer (NSCLC).

This approval broadens the treatment options for patients with solid tumors that test positive for the NTRK genetic alteration whose disease continues to progress on standard treatment therapies. The NTRK genetic alteration is not exclusive to lung cancer and applies to any solid cancer tumors where NTRK is present.

As for patients with metastatic NSCLC who test positive for the ROS1 genetic alteration, this latest approval means ROS1 patients now have four targeted therapy treatment options. Read more here.